Privium Fund Management B.V. Lowers Holdings in Moderna, Inc. $MRNA

Privium Fund Management B.V. trimmed its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 54.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 47,000 shares of the company’s stock after selling 56,433 shares during the period. Privium Fund Management B.V.’s holdings in Moderna were worth $1,214,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Parkside Financial Bank & Trust increased its position in Moderna by 19.0% during the second quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock valued at $65,000 after acquiring an additional 375 shares during the last quarter. Probity Advisors Inc. grew its position in shares of Moderna by 2.6% during the 2nd quarter. Probity Advisors Inc. now owns 14,892 shares of the company’s stock worth $411,000 after buying an additional 377 shares in the last quarter. Amalgamated Bank lifted its position in shares of Moderna by 0.6% in the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock worth $1,806,000 after purchasing an additional 408 shares during the period. Rothschild Investment LLC lifted its holdings in Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after buying an additional 446 shares during the period. Finally, 180 Wealth Advisors LLC boosted its position in Moderna by 2.8% during the second quarter. 180 Wealth Advisors LLC now owns 23,928 shares of the company’s stock valued at $660,000 after purchasing an additional 642 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Trading Down 6.0%

NASDAQ MRNA opened at $44.07 on Friday. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $55.20. The stock has a market cap of $17.22 billion, a PE ratio of -5.46 and a beta of 1.17. The stock has a fifty day simple moving average of $33.96 and a 200-day simple moving average of $29.25.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. During the same period in the previous year, the firm earned $0.03 EPS. The business’s revenue was down 45.4% on a year-over-year basis. Research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna announced a global commercialization collaboration with Recordati for its investigational propionic acidemia therapy mRNA‑3927, under which Moderna keeps development control and can receive up to $160M in upfront/near‑term milestones plus royalties — a near‑term cash and de‑risking event for a rare‑disease program. RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA
• Positive Sentiment: Moderna named Dr. David Berman as Chief Development Officer effective March 2, 2026 — a senior hire that could bolster investor confidence in clinical execution and pipeline progression. Dr. David Berman to Join Moderna as Chief Development Officer
• Neutral Sentiment: Barclays has initiated coverage of Moderna, which can influence flows depending on the firm’s rating and target but is not an immediate operational development. Barclays Initiates Coverage on Moderna
• Neutral Sentiment: Public commentary (e.g., Jim Cramer) remains mixed — high-profile media comments can sway retail interest but don’t change fundamentals. Jim Cramer on Moderna: “We Have to Wait and See”
• Negative Sentiment: Chief Medical Officer Jacqueline Miller, a leader on Spikevax and key development executive, will step down effective March 2 — leadership turnover in clinical oversight raises near‑term execution uncertainty. Moderna CMO Jacqueline Miller to step down
• Negative Sentiment: Reports that Moderna is rethinking late‑stage vaccine funding and investor risk allocation have raised concerns about how the company will finance and prioritize its pipeline, compounding worries from prior quarters of falling COVID vaccine revenue and negative EPS. Moderna Rethinks Late Stage Vaccine Funding And Investor Risk Balance

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Citigroup reaffirmed a “neutral” rating on shares of Moderna in a research report on Monday, January 19th. TD Cowen reaffirmed a “hold” rating on shares of Moderna in a report on Thursday. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research note on Thursday, October 23rd. Wolfe Research reaffirmed an “underperform” rating and issued a $17.00 price target on shares of Moderna in a report on Thursday, November 20th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Moderna in a report on Monday, December 1st. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $28.77.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of Moderna stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director directly owned 3,924 shares in the company, valued at approximately $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 10.90% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.